Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (615)	3/24/1999 11:53:00 PM
From: Brian Malloy	Read Replies (1) \| Respond to of 942

It's too late for Rezulin. The drug will probably not be pulled but the FDA will put some type of restrictions on it or mandate certain testing for patients using the drug. There are too many effective Diabetes products on the market that have a better safety profile. Additionally, two competitors will bring out drugs in the same class as Rezulin within the next few months. Unfortunately for WLA it appears that these new drugs due to not have this hepatic toxicity problem in selected patients and they don't require serial liver panels. That leaves WLA with Lipitor and whatever they can get from the AGPH buy out. I'm buying puts on WLA

To: Anthony Wong who wrote (615)	3/25/1999 11:44:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Two Rezulin Panelists Have Ties to Drug's Maker, LA Times Says Bloomberg News March 25, 1999, 9:39 a.m. ET Washington, March 25 (Bloomberg) -- Two new members of an expert panel set to review the safety of Warner Lambert Co.'s diabetes drug Rezulin tomorrow have received money from a diabetes education group funded by Warner Lambert and its Japanese partner, the Los Angeles Times said. The two new members, Mayer Davidson and Saul Genuth, were named to Endocrinologic and Metabolic Drugs Advisory Committee, which will review the safety of Rezulin following reports of deaths from liver damage, the newspaper said. Davidson told the Times he divulged his connections to Warner Lambert to the FDA, and he said he would leave it to the agency to determine whether there was a conflict of interest. Panel members are required to disclose any links they may have to companies they review, and FDA regulations determine whether they are allowed to vote at the meeting. (LAT 3/25 A1 www.latimes.com)